Novartis sees brain-atrophy data as an edge for MS pill Gilenya

Save

Fresh off winning European backing for broader use–which could prompt more multiple sclerosis patients to switch–Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.